Ovarian cancer remains a challenging disease with limited treatment options, especially for the high-grade serous carcinoma (HGSC) subtype.1 In recent years, immunotherapy has emerged as a promising avenue for various cancer types. Despite the progress, its application in ovarian cancer has encountered obstacles that hinder its effectiveness. One of the key challenges is the immunologically “cold” nature of the tumor microenvironment.2 Ovarian tumors often exhibit a low number of infiltrating immune cells, making them less susceptible to immune-mediated destruction.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: